Table 2 Patient characteristics and clinical outcomes to post-axitinib systemic therapy

Interval from End of Axitinib Therapy to Start of Current Therapy Median in weeks (range)

2.0 (0–41.7)^a

37.4 (2.6–93.0)

Treatment

N ( %)

N ( %)

 VEGF inhibitors

18 (72 %)

3 (25 %)

 Sunitinib

8 (32 %)

−0-

 Pazopanib

6 (24 %)

1 (8 %)

 Bevacizumab

4 (16 %)

2 (17 %)

 mTOR inhibitors

7 (28 %)

8 (67 %)

 Everolimus

5 (20 %)

5 (42 %)

 Temsirolimus

2 (8 %)

3 (25 %)

 Other

−0-

1 (8 %)^b

ECOG PS

 0

3 (13 %)

2 (17 %)

 1

19 (79 %)

9 (75 %)

 2

2 (8 %)^a

1 (8 %)

Heng Risk Group

 Favorable

9 (41 %)

3 (30 %)

 Intermediate

12 (55 %)

6 (60 %)

 Unfavorable

1 (5 %)^c

1 (10 %)^d

Best Response

 PD

2 (8 %)

−0-

 SD

13 (42 %)

6 (55 %)

 PD

7 (28 %)

4 (36 %)

 Not evaluable

3 (12 %)

1 (9 %)^a

Reason Treatment Stopped

 PD/Death

17 (68 %)

6 (54 %)

 Toxicity

4 (16 %)

2 (18 %)

Treatment ongoing

4 (16 %)

3 (27 %)

Duration of Treatment (subsequent therapy) Median in months (range)

4.4 (0.2–27.5+)^a

4.8 (0.7–19.1+)^a